Astellas initiates first-in-human trial of ASP2246 for post-stroke movement disorders
Astellas Pharma has launched a first-in-human study of ASP2246 targeting movement problems following stroke.
Asset / Drug
Drug and asset intelligence for ASP2246 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.